دورية أكاديمية
أعرض في EDS

Double sword role of EZH2 in leukemia.

التفاصيل البيبلوغرافية
العنوان: Double sword role of EZH2 in leukemia.
المؤلفون: Safaei S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Division of Hematology and Transfusion Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Hagh MF; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Alivand MR; Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Talebi M; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Gharibi T; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Solali S; Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Division of Hematology and Transfusion Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ssolali@gmail.com.
المصدر: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2018 Feb; Vol. 98, pp. 626-635. Date of Electronic Publication: 2017 Dec 29.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE
أسماء مطبوعة: Publication: Paris : Editions Scientifiques Elsevier
Original Publication: New York, N.Y. : Masson Pub. USA, Inc., c1982-
مواضيع طبية MeSH: Carcinogenesis/*genetics , Enhancer of Zeste Homolog 2 Protein/*genetics , Leukemia/*genetics , Leukemia/*pathology, Animals ; Cell Differentiation/genetics ; Hematologic Neoplasms/genetics ; Humans ; MicroRNAs/genetics
مستخلص: Enhancer of zeste homolog 2 (EZH2), the core component of the polycomb group complex, plays a major role in normal hematopoiesis. The molecular function of EZH2 is to establish H3K27me3 mark on specific genes by which promotes transcriptional repression of target genes. The activity of EZH2 affects the balance between self-renewal and differentiation of hematopoietic stem cells. In addition, EZH2 contributes to the cell cycle regulation in mature lymphocytes. A large number of studies have been performed to identify the implication of EZH2 in tumor development of leukemia. Aberrant expression of EZH2 is increasingly recognized in leukemic malignancies. To clarify its therapeutic potential in hematopoietic malignancies it should be determined whether EZH2 is involved in the pathology of these neoplasms. This paper reviews the current knowledge of the role of EZH2 in the pathogenesis of myeloid and lymphoid leukemia. We will discuss the mechanisms in which microRNAs regulate the expression of EZH2 in different types of leukemias that may provide a means to alter cancer epigenetics associated to tumorogenesis to achieve therapeutic benefits.
(Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
التعليقات: Erratum in: Biomed Pharmacother. 2018 Mar 8;101:786. (PMID: 29525673)
فهرسة مساهمة: Keywords: EZH2; Gene expression; Leukemias
المشرفين على المادة: 0 (MicroRNAs)
EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
تواريخ الأحداث: Date Created: 20180101 Date Completed: 20180813 Latest Revision: 20180813
رمز التحديث: 20231215
DOI: 10.1016/j.biopha.2017.12.059
PMID: 29289837
قاعدة البيانات: MEDLINE
الوصف
تدمد:1950-6007
DOI:10.1016/j.biopha.2017.12.059